Feasibility study of postoperative adjuvant therapy using S-1 after curative esophagectomy for esophageal cancer

Feasibility study of postoperative adjuvant therapy using S-1 (Tegafur/Gimeracil/Oteracil Potassium) after curative esophagectomy for esophageal cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1060220042

Enrollment

Registered

2022-07-09

Start date

2022-07-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically confirmed esophageal squamous cell carcinoma or adenocarcinoma. 2) Postoperative adjuvant chemotherap using S-a was performed. 3) Curative gastrectomy was performed. 4) Performance status of 0-1 on the Eastern Cooperative Oncology Group classification 5) No prior chemotherapy, radiation, endcrine, molecular targeted therapy within 5 years including treatment for other cancers, 6) Sufficient oral intake.

Exclusion criteria

Exclusion criteria: (1)Double cancer (2)Heart failure, hepatitis, renal dysfunction (3)Severe infection

Design outcomes

Primary

Measure	Time frame
Safety and feasibility of the administration of S-1 adjuvant chemotherapy for patients who underwent thoracoscopic esophagectomy with and without preoperative treatment.	—

Secondary

Measure	Time frame
Overall Survival Disease free survival Adverse events due to S-1 Relative dose intensity	—

Contacts

Public ContactNoriyuki Hirahara

Department of Digestive and General Surgery

norinori@med.shimane-u.ac.jp+81-853-20-2232

Outcome results